abstract |
The present invention is directed to co-crystals of L-proline and citric acid of (2S, 3R, 4R, 5S, 6R) -2- (3 - ((5- (4-fluorophenyl) thiophene-2 -iI) methyl) - 4-methylphenhl) -6- (hydroxymethyl) tetrahydro-2H-pyran-3,4,5-triol, pharmaceutical compositions containing these co-crystals, and their use in the treatment of glucose-related disorders, such as diabetes mellitus type 2 and syndrome X. |